Literature DB >> 21605092

Mohs surgery in Australia: a survey of work practices.

Tim Rutherford1, Tim Elliott, Carl Vinciullo.   

Abstract

BACKGROUND: Mohs micrographic surgery is the preferred treatment for certain skin cancers. It had already been considerably refined prior to its introduction into Australia in 1978, refinement has continued since. Documenting the work practices of Australian Mohs surgeons serves to clarify the current role of Mohs surgery and may help tailor future Mohs fellowship programs.
METHODS: A survey was conducted to investigate the characteristics and clinical practices of Australian Mohs surgeons, particularly as they relate to skin cancer management and aesthetic dermatology.
RESULTS: The typical Australian Mohs surgeon is male (90%), works in a group private practice (70%), and is aged 40-44 years (37%). Mohs surgery is generally reserved for tumours that are located on the head, neck, digits or genitals (98%), and flap reconstructions are the commonest repair types performed (48%). Laser and cosmetic injectable treatments form part of many Mohs surgeon's repertoires.
CONCLUSION: Australian Mohs surgeons make an important contribution to the management of skin cancer in Australia and many are skilled in laser and cosmetic procedures. The increasing number of cases performed annually and the familiarity with laser and cosmetic therapies reinforces Australian dermatologists as leaders in these important areas of dermatology.
© 2011 The Authors. Australasian Journal of Dermatology © 2011 The Australasian College of Dermatologists.

Entities:  

Mesh:

Year:  2011        PMID: 21605092     DOI: 10.1111/j.1440-0960.2011.00751.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  1 in total

1.  [The role of the micrographic surgery in the management of basal cell carcinoma: experience in the Department of Dermatology, at the Hassan II University Hospital, Fes, Morocco].

Authors:  Salim Gallouj; Niema Aqil; Taoufiq Harmouch; Fatima Zahra Mernissi
Journal:  Pan Afr Med J       Date:  2019-07-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.